Not all plasma cells are made equal: well-hidden layers of heterogeneity - Report - MDSpire

Not all plasma cells are made equal: well-hidden layers of heterogeneity

  • By

  • Audrey Anoh Akessé

  • Amélie Bonaud

  • May 11, 2026

  • 0 min

Share

Clinical Report: The Diverse Nature of Plasma Cells: Uncovering Hidden Layers of Heterogeneity

Overview

Recent findings reveal that plasma cells (PCs) are highly heterogeneous, challenging previous notions of their uniformity. Long-lived plasma cells (LLPCs) can arise from various B cell precursors and persist in diverse tissue environments, influenced by intrinsic and extrinsic factors.

Background

Plasma cells are crucial for humoral immunity, producing antibodies that protect against pathogens. Understanding their heterogeneity is vital, as disruptions in PC development can lead to autoimmune diseases and malignancies like multiple myeloma. The evolving insights into PC biology are essential for developing targeted therapies and improving patient outcomes.

Data Highlights

No numerical data presented in the article.

Key Findings

  • Plasma cells exhibit significant molecular, phenotypic, and functional heterogeneity.
  • Long-lived plasma cells can originate from various B cell precursors, not just germinal center B lymphocytes.
  • Heterogeneity among plasma cells is influenced by factors such as B cell lineage, antigen affinity, and tissue-specific microenvironments.
  • Temporal factors, including age and inflammatory conditions, affect plasma cell differentiation and longevity.
  • Approximately 60-70% of the total plasma cell transcriptome consists of immunoglobulin mRNAs, complicating the analysis of their heterogeneity.

Clinical Implications

Detail how understanding heterogeneity can lead to specific treatment advancements.

Conclusion

The recognition of plasma cell heterogeneity underscores the complexity of immune responses and highlights the need for ongoing research to inform clinical practices and therapeutic developments.

Related Resources & Content

  1. Blood Cancer Journal, Increased Non-Clonal Plasma Cell Proportion at Diagnosis Correlates with Better Prognosis in Multiple Myeloma, 2025
  2. Blood Cancer Journal, Characterizing the Bone Marrow Plasma Proteome in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, 2025
  3. Frontiers in Immunology, Why are long-lived plasma cells long-lived?, 2026
  4. Nature Cancer, Decoding tumor heterogeneity and plasticity, 2026
  5. NCCN GUIDELINES® INSIGHTS, Multiple Myeloma, 2023
  6. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis, 2023
  7. Real-world incidence of severe infections in multiple myeloma patients receiving bispecific antibodies: a meta-analysis, 2026
  8. CE NCCN GUIDELINES® INSIGHTS Multiple Myeloma, Ver
  9. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial - ScienceDirect
  10. Real-world incidence of severe infections in multiple myeloma patients receiving bispecific antibodies: a meta-analysis | Annals of Hematology | Springer Nature Link

Original Source(s)

Related Content